ANALYSIS OF EXPEDIENCY TO USE PLATELET-ENRICHED PLASMA FOR TREATMENT OF ANDROGENETIC ALOPECIA

2020 ◽  
pp. 64-67
Author(s):  
Yu. S. Ovcharenko ◽  
O. A. Salyenkova
Keyword(s):  
Growth Factors ◽  
Hair Growth ◽  
Platelet Rich Plasma ◽  
Biological Effects ◽  
Practical Experience ◽  
Biologically Active ◽  
Androgenetic Alopecia ◽  
Published Data ◽  
Active Components ◽  
Characteristic Features

A detailed analysis of the published data on the use of platelet−enriched plasma for the treatment of androgenetic alopecia has been performed. Based on the results, it has been suggested that platelet−rich plasma may be considered as a new treatment for pathological hair−related conditions, including androgenetic alopecia. Information on platelet morphology, characteristics of biologically active substances released from activated platelets have been provided. It has been substantiated that platelets play a crucial role in hemostasis and tissue regeneration by stimulating the cell chemotaxis, proliferation, differentiation, angiogenesis and deposition of the extracellular matrix. Among the many active components of platelets involved into the recovery of damaged tissue, the growth factors have been particularly noted. The influence of growth factors on the regulation of hair growth cycles has been established. Based on the analysis of their biological effects, the diversity of their action in the regulation of hair growth has been emphasized. Characteristic features of some growth factors, insulin−like growth factor (IGF), have been determined and described, their role in damaged tissue repair, angiogenesis, proliferation and cell differentiation has been noted. The practical experience of application of platelet−enriched plasma in various branches of medicine is summarized, proposals concerning the use of this method as a new way of treatment of androgenetic alopecia have been provided. The question of standardization of this method, study and substantiation of differentiated use of platelet−enriched plasma depending on the stage of androgenetic alopecia in men and women remains debatable. Key words: androgenetic alopecia, platelet−enriched plasma, platelets, growth factors.

scholarly journals Ordinary and Activated Bone Grafts: Applied Classification and the Main Features

2015 ◽  
Vol 2015 ◽  
pp. 1-19 ◽  
Author(s):  
R. V. Deev ◽  
A. Y. Drobyshev ◽  
I. Y. Bozo ◽  
A. A. Isaev
Keyword(s):  
Growth Factors ◽  
Biological Effects ◽  
Bone Grafts ◽  
Bone Substitutes ◽  
Bone Defects ◽  
Biologically Active ◽  
Active Components ◽  
Or Gene ◽  
Large Bone ◽  
Large Bone Defects

Bone grafts are medical devices that are in high demand in clinical practice for substitution of bone defects and recovery of atrophic bone regions. Based on the analysis of the modern groups of bone grafts, the particularities of their composition, the mechanisms of their biological effects, and their therapeutic indications, applicable classification was proposed that separates the bone substitutes into “ordinary” and “activated.” The main differential criterion is the presence of biologically active components in the material that are standardized by qualitative and quantitative parameters: growth factors, cells, or gene constructions encoding growth factors. The pronounced osteoinductive and (or) osteogenic properties of activated osteoplastic materials allow drawing upon their efficacy in the substitution of large bone defects.

scholarly journals Platelet-Rich Plasma and Micrografts Enriched with Autologous Human Follicle Mesenchymal Stem Cells Improve Hair Re-Growth in Androgenetic Alopecia. Biomolecular Pathway Analysis and Clinical Evaluation

Biomedicines ◽  
2019 ◽  
Vol 7 (2) ◽  
pp. 27 ◽  
Author(s):  
Pietro Gentile ◽  
Maria G. Scioli ◽  
Alessandra Bielli ◽  
Barbara De Angelis ◽  
Ciro De Sio ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Growth Factors ◽  
Hair Growth ◽  
Cellular Proliferation ◽  
Platelet Rich Plasma ◽  
Androgenetic Alopecia ◽  
Dermal Papilla Cells ◽  
Molecular Pathway ◽  
Baseline Values

Platelet rich plasma (PRP) and Micrografts containing human follicle mesenchymal stem cells (HF-MSCs) were tried as a potential treatment for androgenetic alopecia (AGA). However, little to no work has yet to be seen wherein the bio-molecular pathway of HF-MSCs or PRP treatments were analyzed. The aims of this work are to report the clinical effectiveness of HF-MSCs and platelet-rich plasma evaluating and reviewing the most updated information related to the bio-molecular pathway. Twenty-one patients were treated with HF-MSCs injections and 57 patients were treated with A-PRP. The Wnt pathway and Platelet derived-growth factors effects were analyzed. 23 weeks after the last treatment with mean hair thickness increments (29 ± 5.0%) over baseline values for the targeted area. 12 weeks after the last injection with A-PRP mean hair count and hair density (31 ± 2%) increases significantly over baseline values. The increment of Wnt signaling in Dermal Papilla Cells evidently is one of the principal factors that enhances hair growth. Signaling from mesenchymal stem cells and platelet derived growth factors positively influences hair growth through cellular proliferation to prolong the anagen phase (FGF-7), inducing cell growth (ERK activation), stimulating hair follicle development (β-catenin), and suppressing apoptotic cues (Bcl-2 release and Akt activation).

The Therapeutic Response of Platelet Rich Plasma (PRP) for Androgenetic Alopecia Showed No Correlation with Growth Factors and Platelet Number

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2637-2637 ◽  
Author(s):  
Bruno Lima Rodrigues ◽  
Silmara Aparecida De Lima Montalvão ◽  
Joyce Annichinno-Bizzacchi ◽  
Rebeca Cancela ◽  
Francesca Silva ◽  
...  
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Hair Loss ◽  
Hair Growth ◽  
Therapeutic Response ◽  
Platelet Rich Plasma ◽  
Androgenetic Alopecia ◽  
Autologous Serum ◽  
Platelet Number ◽  
The Mean

Abstract Background: Androgenetic alopecia (AGA) is characterized by a pattern hair loss. Currently, treatment with platelet-rich plasma (PRP) has shown promising results due to the growth factors (GFs) released by the platelets. However, the analysis of therapeutic response according to GFs levels and platelet number in PRP has not been established. Objective: Investigate the therapeutic response to treatment of AGA using a standard method of PRP preparation, and the relation with GFs levels and platelet number. Methods: Inclusion criteria comprised diagnosis of AGA-III-vertex profile according to the Norwood-Hamilton scale, age between 18 and 50 years. Exclusion criteria comprised female gender, previous hair transplantation, any disease related to hair loss such as thyroid disease and/or iron deficiency, neoplasia present or past, kidney, liver, infectious, hematologic or rheumatoid disease, use of antiplatelet and/or anti-inflammatory drugs. All patients provided written informed consent approved by the ethic committee from the Faculty of Medical Sciences of the State University of Campinas (UNICAMP). The protocol comprised 20 subcutaneous injections of 100 µL in the scalp totaling 4 applications every fifteen days, with evaluation performed pretreatment (t0), 45 (t1) and 150 (t2) days after the start of the protocol. The endpoints for therapeutic response were hair growth and increase of percentage of anagen hairs evaluated by TrichoScan. For each patient 40 mL of peripheral blood were collected in ACD tubes. L-PRP (PRP with leukocytes) was performed, with double centrifugation (300 g for 5 minutes, and 700 g for 17 minutes). The platelets were counted in the baseline and in the PRP samples. PRP was activated with autologous serum. The platelet-derived growth factors (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) were measured by Luminex technique (Millipore®, USA), in two different PRP samples from each patient. Results: During the period of August to December of 2014, 15 male patients were included in the study. The median of platelets in PRP was increased by 5 folds in all four PRP preparations with a minimum of 728.9 and maximum 1.901,90 x 106 cel/uL, and median values of 1.082 x 106 cel/uL (range 608 - 2.023). The baseline number of platelets and PRP preparation showed a significant correlation (r = 0.839, p < 0.0001). The variability of platelet numbers from each individual during the four applications was 19.7% with a minimum of 0.50% and a maximum 56.3%. GF quantification of two different PRP preparations showed a similar intra-individual variation, with a mean of variability coefficient of 18.4% for VEGF, 20.9% for PDGF, and 21.6% for EGF (Table 1). EGF and PDGF concentrations showed a significant correlation to PRP platelets number (r = 0.8287 and P < 0.0001, and r = 0.6925 and P=0.0014, respectively) (Figure 1). Our results showed a significant increase in hair count (P = 0.0018) and anagen hairs (P = 0.0070) in 86.6% and 53.3% of patients, respectively. However, no correlation was found between platelet counts and GFs levels with therapeutic response. The patients who presented high levels of GFs did not show better results for hair growth or anagen hair than who presented lower levels. Conclusion: Our results corroborate previous studies that showed PRP as a quite promising therapeutic option for AGA, up to 3 months after the injections. However, there was a lack of correlation between the therapeutic responses and platelet numbers or GFs levels. Although, the GFs were not considered biomarker for PRP, it may play an important role in the PRP therapeutic effect. In addition, our results suggest that the PRP effects depend on an orchestration between many mechanisms involved in the increase of number of hairs and its growth. Furthermore, local receptors might present a central role in this response. Graphs of correlation between the platelet mean in PRP and the mean of the growth factor concentrations Graphs of correlation between the platelet mean in PRP and the mean of the growth factor concentrations Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

PRP application in dermatology: review of current approaches

2021 ◽  
pp. 55-58
Author(s):  
V. V. Bondarenko
Keyword(s):  
Growth Factors ◽  
Blood Plasma ◽  
Tissue Repair ◽  
Skin Diseases ◽  
Platelet Rich Plasma ◽  
Autologous Blood ◽  
Biologically Active ◽  
Tissue Repair And Regeneration ◽  
Positive Results ◽  
Active Substances

In recent years, the possibilities of a dermatologist in the treatment of patients with chronic dermatoses have significantly expanded due to the emergence of new highly effective methods, such as autologous blood plasma enriched with platelet-rich-growth factors (platelet-rich-plasma, PRP). The positive results of using this technology due to its constituent growth factors, cytokines and other biologically active substances, which have a pronounced normalizing effect on the processes of tissue repair and regeneration, expands the possibilities of its use in such skin diseases as erosive and ulcerative lichen planus, scleroatrophic lichen, acne and post-acne. The aim of this review was to analyze the literature on the mechanisms of PRP action in patients with dermatological diseases.

scholarly journals Plants as potential active components in treatment of androgenetic alopecia

2014 ◽  
Vol 60 (1) ◽  
pp. 49-56 ◽  
Author(s):  
Renata Dawid-Pać ◽  
Maria Urbańska ◽  
Ilona Dębosz ◽  
Gerard Nowak
Keyword(s):  
Sex Hormones ◽  
Growth Phase ◽  
Hair Growth ◽  
Raw Materials ◽  
Hair Follicles ◽  
Androgenetic Alopecia ◽  
Active Components ◽  
Plant Raw Materials ◽  
Reductase Inhibitors ◽  
Hereditary Factors

Summary Androgenetic alopecia is caused by the influence of sex hormones on hair follicles and by hereditary factors. Characteristic for that type of alopecia is shortening of the hair growth phase and elongation of the rest phase caused by disturbance of the process of transformation of testosterone into dihydrotestosterone. Treatment of that type of alopecia involves 5α-reductase inhibitors, antagonists of the androgenic receptor or stimulating proliferation of cells to induce the hair growth. A number of plant raw materials work that way, thus they can be used in treatment of this type of alopecia.

scholarly journals Ordinary and Activated Osteoplastic Materials

2015 ◽  
Vol 22 (1) ◽  
pp. 51-69
Author(s):  
R. V Deev ◽  
A. Yu Drobyshev ◽  
I. Ya Bozo
Keyword(s):  
Growth Factors ◽  
Medical Devices ◽  
Bone Defects ◽  
Biological Action ◽  
Biologically Active ◽  
Active Components ◽  
Qualitative And Quantitative ◽  
Or Gene ◽  
Large Bone ◽  
Large Bone Defects

Osteoplastic materials are highly required medical devices for bone defects substitution and filling the areas of bone tissue atrophy. Based on analysis of modern groups of osteoplastic materials, features of their composition, mechanisms of biological action, and indications for clinical use, the applied classification which divides the medical items into ordinary and activated categories is proposed. The main differential criterion is the presence of certain biologically active components in the material composition: growth factors, cells or gene constructions encoding growth factors that are standardized by qualitative and quantitative parameters. Pronounced osteoinductive and (or) osteogenic properties of activated osteoplastic materials enable counting on their effectiveness in replacement of large bone defects.

scholarly journals Ovarian Rejuvenation Using Autologous Platelet-Rich Plasma

Endocrines ◽  
2021 ◽  
Vol 2 (1) ◽  
pp. 15-27
Author(s):  
Tuyen Kim Cat Vo ◽  
Yuka Tanaka ◽  
Kazuhiro Kawamura
Keyword(s):  
Growth Factors ◽  
Platelet Rich Plasma ◽  
Controlled Trial ◽  
Infertility Treatment ◽  
Published Data ◽  
High Concentration ◽  
Treatment Needs ◽  
Initial Report ◽  
Plasma Fraction ◽  
Autologous Platelet Rich Plasma

Advanced maternal age is associated with the natural oocyte depletion, leading to low oocyte yield, high infertility treatment cancellation rates, and eventual decreases in pregnancy rates. Various innovative interventions have been introduced to improve the outcome of infertility treatment for aging patients. Numerous published data demonstrated that early follicle development was regulated by intraovarian growth factors through autocrine or paracrine mechanisms. Platelet-rich plasma (PRP), a plasma fraction of peripheral blood with a high concentration of platelets, has been implemented in regenerative medicine in the last decade. The plasma contains a variety of growth factors that were suggested to be able to enhance angiogenesis regeneration and the cell proliferation process. The initial report showed that an intraovarian injection of PRP improved the hormonal profile and increased the number of retrieved oocytes in patients with diminished ovarian reserve. Subsequently, several studies with larger sample sizes have reported that this approach resulted in several healthy live births with no apparent complications. However, the use of ovarian PRP treatment needs to be fully investigated, because no randomized controlled trial has yet been performed to confirm its efficacy.

scholarly journals Current Insights into the Potential Misuse of Platelet-based Applications for Doping in Sports

2019 ◽  
Vol 40 (07) ◽  
pp. 427-433 ◽  
Author(s):  
David Scully ◽  
Antonios Matsakas
Keyword(s):  
Growth Factors ◽  
Cell Function ◽  
Platelet Rich Plasma ◽  
Biological Effects ◽  
Energy Utilization ◽  
Competitive Sports ◽  
The World ◽  
Doping In Sports ◽  
Platelet Releasate ◽  
World Anti Doping Agency

AbstractPlatelet-based applications are currently used for the delivery of growth factors and other biomolecules as autologous biomaterials in regenerative medicine and cosmetic therapies. Many studies have revealed that platelet-based applications such as platelet-rich plasma and platelet releasate exhibit beneficial biological effects after a sports injury or trauma when administered locally by intramuscular injections. At present, treatment of the public, patients and athletes with platelet-based applications is permitted and regulated by the Food and Drug Administration and the World Anti-Doping Agency. Since 2011 the use of autologous platelet-rich plasma is permitted in competitive sports by the World Anti-Doping Agency, due to the lack of evidence in performance enhancement and anabolic effects. However, accumulating research has recently shed light on the role of platelet-derived growth factors in wound healing, skeletal myogenesis, muscle stem cell function and tissue regeneration. Although any ergogenic potential of platelet-rich plasma and platelet releasate on intact skeletal muscle and human sports performance remain to be established, novel evidence suggests that platelet-derived growth factors can modulate muscle, tendon, ligament, protein synthesis/degradation, vascularization, energy utilization and regenerative capacity in various experimental settings. Since platelet-based applications are currently not prohibited, they constitute a tool for potential abuse and doping in sports. The aim of this review is to critically discuss and assimilate current insights and biological evidence that set the ground for exploitation and misuse in competitive sports, and develop strategies to combat these activities.

Sign in / Sign up

Export Citation Format

Share Document